BRCA1 and neoplasm: Currently, all PARPi are licenced for continuous, daily dosing and this schedule has been informed by clinical studies.45,46 Pre-clinical work demonstrated some delay in tumour progression with intermittent scheduling of PARPi in BRCA-1 deficient mice.47 An adaptive dosing approach, which adjusts PARPi dosing based on tumour dynamics, has been examined in OC cell populations using mathematical modelling and in vitro experiments.